Patents Assigned to DRG International, Inc.
  • Patent number: 8304197
    Abstract: The present invention concerns methods for detecting a hepcidin precursor in a sample from a patient and involves contacting the sample with an antibody or fragment thereof that specifically binds to one or more epitopes of a hepcidin precursor amino acid sequence located within amino acids 20-50 of SEQ ID NO: 2.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: November 6, 2012
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Patent number: 8304258
    Abstract: The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: November 6, 2012
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko
  • Patent number: 8263352
    Abstract: The present invention concerns a method of detecting hepcidin, prohepcidin or fragments thereof, by contacting the sample with an antibody or fragment thereof that specifically binds to one or more epitopes contained within amino acids 28-47 of SEQ ID NO:2.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 11, 2012
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Jentzko, Wolfgang Stremmel
  • Publication number: 20120003696
    Abstract: The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition.
    Type: Application
    Filed: August 23, 2011
    Publication date: January 5, 2012
    Applicant: DRG INTERNATIONAL, INC.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko
  • Publication number: 20110287448
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
    Type: Application
    Filed: July 8, 2011
    Publication date: November 24, 2011
    Applicant: DRG INTERNATIONAL, INC.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Publication number: 20110275099
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.
    Type: Application
    Filed: July 18, 2011
    Publication date: November 10, 2011
    Applicant: DRG INTERNATIONAL, INC.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Patent number: 8003338
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: August 23, 2011
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Patent number: 7998691
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: August 16, 2011
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Publication number: 20100330595
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
    Type: Application
    Filed: May 24, 2010
    Publication date: December 30, 2010
    Applicant: DRG International Inc.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Publication number: 20100086945
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.
    Type: Application
    Filed: December 2, 2009
    Publication date: April 8, 2010
    Applicant: DRG International Inc.
    Inventors: Hasan Kulaksiz, Cyrill E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Patent number: 7649081
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: January 19, 2010
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Patent number: 7411048
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: August 12, 2008
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Patent number: 7320894
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: January 22, 2008
    Assignee: DRG International, Inc.
    Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
  • Publication number: 20040096990
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
    Type: Application
    Filed: May 19, 2003
    Publication date: May 20, 2004
    Applicant: DRG International , Inc.
    Inventors: Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel, Hasan Kulaksiz
  • Publication number: 20040096987
    Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.
    Type: Application
    Filed: November 19, 2002
    Publication date: May 20, 2004
    Applicant: DRG International, Inc.
    Inventors: Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel, Hasan Kulaksiz